Literature DB >> 17588356

Sarcoma molecular testing: diagnosis and prognosis.

Alexander J F Lazar1, Jonathan C Trent, Dina Lev.   

Abstract

Methodologies employed in the rapidly developing field of soft tissue sarcoma molecular testing focus primarily on diagnosis using chromosomal translocations and the resulting fusion transcripts. Molecular prognostic testing holds promise in this complex group of rare mesenchymal malignancies, but results are preliminary and require further confirmation. Analysis of activating KIT mutations in gastrointestinal stromal tumors is currently being used in management of patient therapy.

Entities:  

Mesh：

Year:  2007        PMID： 17588356     DOI： 10.1007/s11912-007-0038-8

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  47 in total

1.  Clear cell hidradenoma of the skin-a third tumor type with a t(11;19)--associated TORC1-MAML2 gene fusion.

Authors:  Afrouz Behboudi; Marta Winnes; Ludmila Gorunova; Joost J van den Oord; Fredrik Mertens; Fredrik Enlund; Göran Stenman
Journal:  Genes Chromosomes Cancer       Date:  2005-06       Impact factor: 5.006

2.  Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Charles D Blanke; George D Demetri; Heikki Joensuu; Peter J Roberts; Burton L Eisenberg; Margaret von Mehren; Christopher D M Fletcher; Katrin Sandau; Karen McDougall; Wen-bin Ou; Chang-Jie Chen; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2006-09-05       Impact factor: 44.544

3.  EWS-CREB1: a recurrent variant fusion in clear cell sarcoma--association with gastrointestinal location and absence of melanocytic differentiation.

Authors:  Cristina R Antonescu; Khedoudja Nafa; Neil H Segal; Paola Dal Cin; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

4.  Molecular characterisation of soft tissue tumours: a gene expression study.

Authors:  Torsten O Nielsen; Rob B West; Sabine C Linn; Orly Alter; Margaret A Knowling; John X O'Connell; Shirley Zhu; Mike Fero; Gavin Sherlock; Jonathan R Pollack; Patrick O Brown; David Botstein; Matt van de Rijn
Journal:  Lancet       Date:  2002-04-13       Impact factor: 79.321

5.  TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

Authors:  Scott A Tomlins; Rohit Mehra; Daniel R Rhodes; Lisa R Smith; Diane Roulston; Beth E Helgeson; Xuhong Cao; John T Wei; Mark A Rubin; Rajal B Shah; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

Review 6.  A mucoepidermoid carcinoma of minor salivary gland with t(11;19)(q21;p13.1) as the only karyotypic abnormality.

Authors:  A K El-Naggar; M Lovell; A M Killary; G L Clayman; J G Batsakis
Journal:  Cancer Genet Cytogenet       Date:  1996-03

7.  Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis.

Authors:  Louis Guillou; Jean Benhattar; Françoise Bonichon; Gabrielle Gallagher; Philippe Terrier; Edouard Stauffer; Nicolas de Saint Aubain Somerhausen; Jean-Jacques Michels; Gernot Jundt; Dominique Ranchère Vince; Sophia Taylor; Muriel Genevay; Françoise Collin; Martine Trassard; Jean-Michel Coindre
Journal:  J Clin Oncol       Date:  2004-09-13       Impact factor: 44.544

Review 8.  Biology of gastrointestinal stromal tumors.

Authors:  Christopher L Corless; Jonathan A Fletcher; Michael C Heinrich
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

9.  Mammalian chromosomes in vitro. IV. Some human neoplasms.

Authors:  T C HSU
Journal:  J Natl Cancer Inst       Date:  1954-02       Impact factor: 13.506

10.  The predictive potential of molecular detection in the nonmetastatic Ewing family of tumors.

Authors:  Smadar Avigad; Ian J Cohen; Julia Zilberstein; Ella Liberzon; Yacov Goshen; Shifra Ash; Isaac Meller; Yehuda Kollender; Josephine Issakov; Rina Zaizov; Isaac Yaniv
Journal:  Cancer       Date:  2004-03-01       Impact factor: 6.860
View more
  5 in total

Review 1.  Gene translocations in musculoskeletal neoplasms.

Authors:  Balaji Krishnan; Gaurav Khanna; Denis Clohisy
Journal:  Clin Orthop Relat Res       Date:  2008-06-20       Impact factor: 4.176

2.  Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing.

Authors:  Françoise Ducimetière; Antoine Lurkin; Dominique Ranchère-Vince; Anne-Valérie Decouvelaere; Michel Péoc'h; Luc Istier; Philippe Chalabreysse; Christine Muller; Laurent Alberti; Pierre-Paul Bringuier; Jean-Yves Scoazec; Anne-Marie Schott; Christophe Bergeron; Dominic Cellier; Jean-Yves Blay; Isabelle Ray-Coquard
Journal:  PLoS One       Date:  2011-08-03       Impact factor: 3.240

3.  Descriptive epidemiology of soft tissue sarcomas and gastrointestinal stromal tumors in Thailand.

Authors:  Jeerawan Klangjorhor; Donsuk Pongnikorn; Pattaralawan Sittiju; Areerak Phanphaisarn; Parunya Chaiyawat; Pimpisa Teeyakasem; Patiwat Kongdang; Sutpirat Moonmuang; Narate Waisri; Karnchana Daoprasert; Taweechok Wisanuyotin; Chalongpon Santong; Siriphon Sitthikong; Pakjai Tuntarattanapong; Paradee Prechawittayakul; Dumnoensun Pruksakorn
Journal:  Sci Rep       Date:  2022-07-27       Impact factor: 4.996

4.  Assessment of fusion gene status in sarcomas using a custom made fusion gene microarray.

Authors:  Marthe Løvf; Gard O S Thomassen; Fredrik Mertens; Nuno Cerveira; Manuel R Teixeira; Ragnhild A Lothe; Rolf I Skotheim
Journal:  PLoS One       Date:  2013-08-13       Impact factor: 3.240

5.  Lipid Nanoparticles Decorated with TNF-Related Aptosis-Inducing Ligand (TRAIL) Are More Cytotoxic than Soluble Recombinant TRAIL in Sarcoma.

Authors:  Ana Gallego-Lleyda; Diego De Miguel; Alberto Anel; Luis Martinez-Lostao
Journal:  Int J Mol Sci       Date:  2018-05-13       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.